Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations

Am J Hematol. 2015 May;90(5):E93-4. doi: 10.1002/ajh.23949. Epub 2015 Feb 17.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols*
  • Bone Marrow / drug effects
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Bone Marrow Transplantation
  • CCAAT-Enhancer-Binding Proteins / genetics*
  • Child
  • Child, Preschool
  • DNA Mutational Analysis
  • Exons
  • Female
  • GATA2 Transcription Factor / genetics*
  • Gene Expression
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Mutation*
  • Nuclear Proteins / genetics
  • Nucleophosmin
  • Recurrence
  • Survival Analysis
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • CCAAT-Enhancer-Binding Proteins
  • CEBPA protein, human
  • GATA2 Transcription Factor
  • GATA2 protein, human
  • Nuclear Proteins
  • Nucleophosmin
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3